Photo from Diko Kazandjian/X
Jun 5, 2024, 14:51
Diko Kazandjian: IsaVRD more is better
Dickran (Diko) Kazandjian, Professor of Medicine at the Sylvester Comprehensive Cancer Center and Board Member of OncoDaily, shared on X/Twitter:
”IsaVRD (Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (VRD)). More is better. For transplant-eligible patients with newly diagnosed multiple myeloma who are under 80 years old.”
Source: Diko Kazandjian/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 19, 2024, 10:18
Nov 19, 2024, 10:05
Nov 19, 2024, 09:53
Nov 19, 2024, 09:44
Nov 19, 2024, 09:40
Nov 19, 2024, 09:28